Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.

Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.

Sintilimab treatment caused hair loss but led to complete tumor remission.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

Ixekizumab may be an effective first treatment for a rare skin condition causing hair loss.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.

Dupilumab effectively controls symptoms in infants with Netherton syndrome.

Cromolyn sodium's effectiveness for treating asthma in children under 2 is unclear, possibly more beneficial for older children, and further research is needed.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

Brodalumab effectively treated a man's severe hand and foot psoriasis.

Mycophenolate mofetil helped reduce steroid use in treating a dog's autoimmune skin disease.

Troglitazone increases subcutaneous fat in lipodystrophy patients.

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.

Talquetamab may cause hair loss and skin issues.

The document concludes that diagnosing and treating Interstitial Pneumonia with Autoimmune Features (IPAF) is challenging, needs a multidisciplinary approach, and further research for better diagnostic criteria and treatments. It also emphasizes regular checks for Connective Tissue Disease symptoms in all patients with Interstitial Lung Disease.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Anifrolumab helped some lupus patients reduce steroid use, but safety concerns remain.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

FOLFOX6 chemotherapy effectively reduces VEGF levels and improves quality of life in advanced colorectal cancer patients.

Promising cancer treatments were found, but the manufacturer closed.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.